163
Barrett’s adenocarcinoma in a mouse xenograft
model. Mol Cancer Ther 12(3):255–263.
https://doi.org/10.1158/1535-7163.
mct-12-0777
- Ford SJ, Obeidy P, Lovejoy DB, Bedford M,
Nichols L, Chadwick C, Tucker O, Lui GY,
Kalinowski DS, Jansson PJ, Iqbal TH, Alderson
D, Richardson DR, Tselepis C (2013)
Deferasirox (ICL670A) effectively inhibits
esophageal cancer growth in vitro and in vivo.
Br J Pharmacol 168(6):1316–1328. https://
doi.org/10.1111/bph.12045
- Lange T, Nentwich MF, Luth M, Yekebas E,
Schumacher U (2011) Trastuzumab has anti-
metastatic and anti-angiogenic activity in a
spontaneous metastasis xenograft model of
esophageal adenocarcinoma. Cancer Lett
308(1):54–61. https://doi.org/10.1016/j.
canlet.2011.04.013
- Liu DS, Hoefnagel SJ, Fisher OM, Krishnadath
KK, Montgomery KG, Busuttil RA, Colebatch
AJ, Read M, Duong CP, Phillips WA, Clemons
NJ (2016) Novel metastatic models of esopha-
geal adenocarcinoma derived from FLO-1 cells
highlight the importance of E-cadherin in can-
cer metastasis. Oncotarget 7(50):83342–
83358. https://doi.org/10.18632/
oncotarget.13391
- Sehdev V, Peng D, Soutto M, Washington MK,
Revetta F, Ecsedy J, Zaika A, Rau TT,
Schneider-Stock R, Belkhiri A, El-Rifai W
(2012) The aurora kinase A inhibitor
MLN8237 enhances cisplatin-induced cell
death in esophageal adenocarcinoma cells. Mol
Cancer Ther 11(3):763–774. https://doi.
org/10.1158/1535-7163.mct-11-0623
- Gros SJ, Dohrmann T, Rawnaq T, Kurschat N,
Bouvet M, Wessels J, Hoffmann RM, Izbicki
JR, Kaifi JT (2010) Orthotopic fluorescent
peritoneal carcinomatosis model of esophageal
cancer. Anticancer Res 30(10):3933–3938
- Sicklick JK, Leonard SY, Babicky ML, Tang
CM, Mose ES, French RP, Jaquish DV, Hoh
CK, Peterson M, Schwab R, Lowy AM (2014)
Generation of orthotopic patient- derived xeno-
grafts from gastrointestinal stromal tumor.
J Transl Med 12:41. https://doi.
org/10.1186/1479-5876-12-41
- Hassan MS, Awasthi N, Li J, Schwarz MA,
Schwarz RE, Holzen UV (2017) A novel intra-
peritoneal metastatic xenograft mouse model
for survival outcome assessment of esophageal
adenocarcinoma. PLoS One 12(2):e0171824.
https://doi.org/10.1371/journal.
pone.0171824
- Garnett MJ, Edelman EJ, Heidorn SJ,
Greenman CD, Dastur A, Lau KW, Greninger
P, Thompson IR, Luo X, Soares J, Liu Q, Iorio
F, Surdez D, Chen L, Milano RJ, Bignell GR,
Tam AT, Davies H, Stevenson JA, Barthorpe S,
Lutz SR, Kogera F, Lawrence K, McLaren-
Douglas A, Mitropoulos X, Mironenko T, Thi
H, Richardson L, Zhou W, Jewitt F, Zhang T,
O’Brien P, Boisvert JL, Price S, Hur W, Yang
W, Deng X, Butler A, Choi HG, Chang JW,
Baselga J, Stamenkovic I, Engelman JA,
Sharma SV, Delattre O, Saez-Rodriguez J,
Gray NS, Settleman J, Futreal PA, Haber DA,
Stratton MR, Ramaswamy S, McDermott U,
Benes CH (2012) Systematic identification of
genomic markers of drug sensitivity in cancer
cells. Nature 483(7391):570–575. https://
doi.org/10.1038/nature11005
- Wilding JL, Bodmer WF (2014) Cancer cell
lines for drug discovery and development.
Cancer Res 74(9):2377–2384. https://doi.
org/10.1158/0008-5472.can-13-2971
- Niu N, Wang L (2015) In vitro human cell line
models to predict clinical response to antican-
cer drugs. Pharmacogenomics 16(3):273–285.
https://doi.org/10.2217/pgs.14.170
- Kresty LA, Weh KM, Zeyzus-Johns B, Perez
LN, Howell AB (2015) Cranberry proanthocy-
anidins inhibit esophageal adenocarcinoma
in vitro and in vivo through pleiotropic cell
death induction and PI3K/AKT/mTOR inac-
tivation. Oncotarget 6(32):33438–33455.
https://doi.org/10.18632/oncotarget.5586
- Lin YS, Hu L, Yin MC (2017) Apoptotic effects
of rotundic acid on human esophagus and lung
cancer cells. Integr Cancer Ther. https://doi.
org/10.1177/1534735416635275
- Boonstra JJ, Tilanus HW, Dinjens WN (2015)
Translational research on esophageal adenocar-
cinoma: from cell line to clinic. Dis Esophagus
28(1):90–96. https://doi.org/10.1111/
dote.12095
- Hasina R, Surati M, Kawada I, Arif Q, Carey
GB, Kanteti R, Husain AN, Ferguson MK,
Vokes EE, Villaflor VM, Salgia R (2013) O-6-
methylguanine-deoxyribonucleic acid methyl-
transferase methylation enhances response to
temozolomide treatment in esophageal cancer.
J Carcinog 12:20. https://doi.
org/10.4103/1477-3163.120632
- Johnson JI, Decker S, Zaharevitz D, Rubinstein
LV, Venditti JM, Schepartz S, Kalyandrug S,
Christian M, Arbuck S, Hollingshead M,
Sausville EA (2001) Relationships between
drug activity in NCI preclinical in vitro and
in vivo models and early clinical trials. Br
J Cancer 84(10):1424–1431. https://doi.
org/10.1054/bjoc.2001.1796
- Kerbel RS (2003) Human tumor xenografts as
predictive preclinical models for anticancer
drug activity in humans: better than commonly
Xenograft Models of Esophageal Adenocarcinoma